Table 4.
Oncological response.
| Characteristic | N | Platinum sensitive N = 116 (60%)1 |
Platinum resistant N = 76 (40%)1 |
p-value2 |
|---|---|---|---|---|
| Morphologic response (RECIST 1.1)* |
100 | 0.16 | ||
| Complete | 12 (20%) | 4 (9.8%) | ||
| Partial | 14 (24%) | 8 (20%) | ||
| Stable | 13 (22%) | 17 (41%) | ||
| Progression | 20 (34%) | 12 (29%) | ||
| Missing | 57 | 35 | ||
| PRGS# | 96 | 0.016 | ||
| PRGS 1 | 15 (26%) | 3 (7.9%) | ||
| PRGS 2 | 22 (38%) | 12 (32%) | ||
| PRGS 3 | 19 (33%) | 16 (42%) | ||
| PRGS 4 | 2 (3.4%) | 7 (18%) | ||
| Missing | 58 | 38 | ||
| Positive cytology* | 64 | 29 (78%) | 19 (70%) | 0.46 |
| Missing | 79 | 49 |
1 n (%).
2 Fisher's exact test; Pearson's Chi-squared test.
* Morphological response according RECIST 1.1 criteria, after 3 PIPAC or at least 2 PIPAC.
# PRGS: Pathological Regression Grading Score; 1= complete response; 2= major response (>50% fibrosis); 3=partial response (<50% fibrosis); 4=no response.